Please login to the form below

Not currently logged in
Email:
Password:

tau

This page shows the latest tau news and features for those working in and with pharma, biotech and healthcare.

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

The company also said it has started dosing patents in a phase 2 trial of its tau protein-targeting Alzheimer’s drug BIIB092, licensed from Bristol-Myers Squibb last year.

Latest news

More from news
Approximately 3 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Acquisition company. 4, 800. Denali

  • Deal Watch - May 2017 Deal Watch - May 2017

    BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for  progressive supranuclear palsy.

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    He believes that “tau has received nothing like the attention that amyloid has by big pharma - they all jump on the bandwagon, unfortunately. ... There are studies progressing with tau as a target, but it will be a while before clear evidence emerges.

  • Pharma deals in May 2015 Pharma deals in May 2015

    1, 100. Sigma Tau/ Baxter. Asset acquisition. Oncaspar (pegasparagase - marketed) portfolio in acute lymphoblastic leukaemia (ALL).

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Exclusive licence. 522. AC Immune/ Janssen. To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Industry round up: appointments Industry round up: appointments

    Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Ryan brings over 15 years of central nervous system clinical research experience to the role, and takes on responsibility for Asceneuron's pipeline of innovative small molecules and progressing tau modifiers ... His outstanding track record and expertise

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Sigma-Tau Pharmaceuticals appoints CEO Sigma-Tau Pharmaceuticals appoints CEO

    Sigma-Tau Pharmaceuticals appoints CEO. Interim CEO Michael Minarich takes up the post in a permanent capacity. ... Rare disease specialist Sigma-Tau Pharmaceuticals has appointed Michael Minarich as chief executive officer.

  • EMA names new head of legal service EMA names new head of legal service

    An Italian national, Marino has extensive legal experience in the pahrma industry, having served as director of corporate legal and intellectual property at pharma firm Sigma-Tau since 1997.

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Forecasting in Forgotten Markets

    From a scientific perspective, the jury is still out on the root cause of these conditions and whether the current hypothesis around the involvement of Amyloid and Tau proteins in different

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics